Predictors of Non-Adherence to Follow-up Visits and Deferasirox Chelation Therapy Among Jordanian Adolescents with Thalassemia Major

REFERENCES

• Borgna-Pignatti C, Rugolotto S, De Stefano P, Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004;89:1187–1193.
   PubMed Web of Science ®Google Scholar
• Agarwal MB. Deferasirox: oral, once daily iron chelator-an expert opinion. Indian J Pediatr. 2010;77(2):185–191.
   PubMed Web of Science ®Google Scholar
• Cappellini MD, Cohen A, Piga A, A phase 3 study of deferasirox (ICL670), a once daily oral iron chelator, in patients with β-Thalassemia. Blood. 2006;107:3455–3462.
   PubMed Web of Science ®Google Scholar
• Neufeld EJ. Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. Blood. 2006;107:3436–3441.
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO). Adherence to long-term therapies evidence for action. Geneva: WHO Library Cataloguing-in-Publication Data; 2003.
   Google Scholar
• Jin J, Sklar GE, OhV LC. Factors affecting therapeutic compliance: a review from patients’ perspective. Ther Clin Risk Manag. 2008;4:269–286.
   PubMedGoogle Scholar
• Taddeo D, Egedy M, Frappier J. Adherence to treatment in adolescents. Paediatr Child Health. 2008;13:19–24.
   PubMed Web of Science ®Google Scholar
• Galanello R, Origa R. Beta-thalassemia. Orphanet J Rare Dis. 2010;5:1–15.
   PubMed Web of Science ®Google Scholar
• Hamamy H. ‘Consanguineous marriages in the Arab world,’ selected studies. The Ambassadors Online Magazine. Vol. 6. Issue 2; July 2003. http://ambassadors.net/archives/issue14/ selected_studies3.htm. Accessed 12 October 2010.
   Google Scholar
• Hamamy H, Al-Hait S, Alwan A, Ajlouni K. Jordan: communities and community genetics. Community Genet. 2007;10(1):52–60.
   PubMedGoogle Scholar
• Aessopos A, Farmakis D, Deftereos S, Thalassemia heart disease, a comparative evaluation of thalassemia major and thalassemia intermedia. Chest. 2005;127:1523–1530.
   PubMed Web of Science ®Google Scholar
• Kwiatkowski JL, Kim HY, Thompson AA, Cohort chelation use and iron burden in North American and British thalassemia patients: a report from the Thalassemia Longitudinal Cohort. Blood. 2012;119:2746–2753.
   PubMed Web of Science ®Google Scholar
• Porter J, Evangeli M, El-Beshlawy A. The challenges of adherence and persistence with iron chelation therapy. Int J Hematol. 2011;94:453–460.
   PubMed Web of Science ®Google Scholar
• Cappellini MD. Iron-chelating therapy with the new oral agent ICL670 (Exjade). Best Pract Res Clin Haematol. 2005;18(2):289–298.
   PubMed Web of Science ®Google Scholar
• Smith K, Gibson V. London new drugs group review of iron chelator (deferasirox, deferiprone, desferrioxamine) for iron overload. 2007. http://www.dialogosuifarmaci.it/documents/London% 20new%20group%202007.pdf. Accessed September 2013.
   Google Scholar
• Cohen AR. New advances in iron chelation therapy. Hematol Am Soc Hematol Educ Program. 2006;1:42–47.
   Google Scholar
• Pai A, Ostendorf HM. Treatment adherence in adolescents and young adults affected by chronic illness during the health care transition from pediatric to adult health care: a literature review. Children's Health Care. 2011;40:16–33.
   Web of Science ®Google Scholar
• Rapoff MA. Adherence to pediatric medical regimens, issues in clinical child. Psychology. 2010;XII:33–45.
   Google Scholar
• World Health Organization (WHO). The adolescent with a chronic condition epidemiology, developmental issues and health care provision. Geneva: WHO Library; 2007.
   Google Scholar
• Ofelia A, Hector R, Natasha R, Adherence to deferasirox in children and adolescents with sickle cell disease during 1-year of therapy. J Pediatr Hematol Oncol. 2009;31(10):739–744.
   PubMed Web of Science ®Google Scholar
• Lee YL, Lin DT, Tsai SF. Disease knowledge and treatment adherence among patients with thalassemia major and their mothers in Taiwan. J Clin Nurs. 2008;18:529–538.
   Web of Science ®Google Scholar
• Jellinek M, Murphy M, Little M, Use of the Pediatric Symptom Checklist to screen for psychosocial problems in pediatric primary care: a national feasibility study. Arch Pediatr Adolesc Med. 1999;153:254–260.
   PubMed Web of Science ®Google Scholar
• Beaton DE, Bombardier C, Guillemin F, Ferraz MB. Guidelines for the process of cross-cultural adaptation of self-report measures. Spine. 2000;25:3186–3191.
   PubMed Web of Science ®Google Scholar
• Saini A, Chandra J, Goswami U, Case control study of psychosocial morbidity in beta thalassemia major. J Pediatr. 2007;150:516–520.
   PubMed Web of Science ®Google Scholar
• Jellinek MS, Murphy JM, Feins SL, Fenton T. The Pediatric Symptom Checklist: screening school-age children for psychosocial dysfunction. J Pediatr. 1988;112:201–209.
   PubMed Web of Science ®Google Scholar
• Murphy JM, Ichinose RC, Hicks DK, Utility of the Pediatric Symptom Checklist as a psychosocial screen to meet the federal Early and Periodic Screening, Diagnosis, and Treatment (EPSDT) standards: a pilot study. J Pediatr. 1996;129(6):864–869.
   PubMed Web of Science ®Google Scholar
• Angulo IL, Covas DT, Carneiro AA, Determination of iron-overload in thalassemia by hepatic MRI and ferritin. Rev Bras Hematol Hemoter. 2008;30(6):449–452.
   Google Scholar
• Vermylen C. What is new in iron overload? Eur J Pediatr. 2008;167:377–381.
   Web of Science ®Google Scholar
• Trachtenberg F, Vichinsky E, Haines D, Iron chelation adherence to deferoxamine and deferasirox in thalassemia. Am J Hematol. 2011;86:433–436.
   PubMed Web of Science ®Google Scholar
• Fragatou S, Tsourveloudis I, Fragatou M, Paterakis P. Investigation of psychiatric factors affecting compliance of transfusion dependent thalassemia patients with iron chelating agents, deferoxamine, deferiprone and deferasirox. Haematologica. 2010;95(192), abs. 0472. http://online.haematologica. org/EHA15/browserecord.php?-action=browse&-recid=6541. Accessed August 2013.
   Google Scholar
• Kipps S, Bahu T, Ong K, Current methods of transfer of young people with type 1 diabetes to adult services. Diabet Med. 2002;19:649–654.
   PubMed Web of Science ®Google Scholar
• Annunziato RA, Emre S, Shneider B, Adherence and medical outcomes in pediatric liver transplant recipients who transition to adult services. Pediatr Transplant. 2007;11:608–614.
   PubMed Web of Science ®Google Scholar
• Watson AR. Non-compliance and transfer from pediatric to adult transplant unit. Pediatr Nephrol. 2000;14:469–472.
   PubMed Web of Science ®Google Scholar
• Atkin K, Ahmad WI. Pumping iron: compliance with chelation therapy among young people who have thalassemia major. Sociol Health Ill. 2000;22:500–524.
   Web of Science ®Google Scholar
• Pritchard MT, Butow PN, Stevens MM, Duley JA. Understanding medication adherence in pediatric acute lymphoblastic leukemia: a review. J Pediatr Hematol Oncol. 2006;28:816–823.
   PubMed Web of Science ®Google Scholar
• Smith B, Wood B. Psychological factors affecting disease activity in children and adolescents with cystic fibrosis: medical adherence as a mediator. Curr Opin Pediatr. 2007;19:553–558.
   PubMed Web of Science ®Google Scholar
• Costello I, Wong IC, Nunn AJ. A literature review to identify interventions to improve the use of medicines in children. Child Care Health Dev. 2004;3:647–665.
   Google Scholar
• Rapoff MA. Management of adherence and chronic rheumatic disease in children and adolescents. Best Pract Res Clin Rheumatol. 2006;20:301–314.
   PubMed Web of Science ®Google Scholar
• Shaw RJ. Treatment adherence in adolescents: development and psychopathology. Clin Child Psychol. 2001;6:137–135.
   Google Scholar
• Wiebe DJ, Berg CA, Korbel C, Children's appraisals of maternal involvement in coping with diabetes: enhancing our understanding of adherence, metabolic control, and quality of life across adolescence. J Pediatr Psychol. 2005;30:167–178.
   PubMed Web of Science ®Google Scholar
• Michaud PA, Suris JC, Viner R. The adolescent with a chronic condition. Part II: healthcare provision. Arch Dis Child. 2004;89:943–949.
   PubMed Web of Science ®Google Scholar
• Ghazanfari Z, Forouzi M, Pouraboli B. Knowledge level and educational needs of thalassemic children's parents in Kerman. IJCCN. 2010;3(3):99–103.
   Google Scholar
• Aydinok Y, Erermis S, Bukusoglu N, Psychosocial implications of thalassemia major. Pediatr Int. 2005;47:84–89.
   PubMed Web of Science ®Google Scholar
• Modi AC, Marciel KK, Slater SK, The influence of parental supervision on medical adherence in adolescents with cystic fibrosis: developmental shifts from pre to late adolescence. Children's Health Care. 2008;37(1):78–82.
   Web of Science ®Google Scholar
• Feinstein S, Keich R, Becker CR, Is noncompliance among adolescent renal transplant recipients inevitable? Pediatrics. 2005;115:969–973.
   PubMed Web of Science ®Google Scholar
• Lansky SB, Cairns NU, Clark GM, Childhood cancer: non medical costs of the illness. Cancer. 1979;43:403–408.
   PubMed Web of Science ®Google Scholar
• Economou M, Zafeiriou DI, Kontopoulos E, Neurophysiologic and intellectual evaluation of beta-thalassemia patients. Brain Dev. 2006;28:14–18.
   PubMed Web of Science ®Google Scholar
• Monastero R, Monastero G, Ciaccio C, Cognitive deficits in beta-thalassemia major. Acta Neurol Scand. 2000;102:162–168.
   PubMed Web of Science ®Google Scholar
• Zafeiriou DI, Economu M, Athanasiou-Metaxa M. Neurological complications in beta-thalassemia. Brain Dev. 2006;28:477–481.
   PubMed Web of Science ®Google Scholar
• McQuaid EL, Kopel SJ, Klein RB, Fritz GK. Medication adherence in pediatric asthma: reasoning, responsibility and behaviour. J Pediatr Psychol. 2003;28:323–333.
   PubMed Web of Science ®Google Scholar
• Kyngäs H, Thilo K, Duffy ME. Compliance in adolescents with chronic diseases: a review. J Adolesc Health. 2000;26(6):379–388.
   PubMed Web of Science ®Google Scholar